Deykin Aaron sold 895 Upstream Bio shares at $5.49 each on Sept. 16, 2026, leaving him with 32,302 shares. The sale represented about 2.7% of his prior Upstream Bio holding, giving investors the disclosed scale of the insider transaction and the remaining ownership position.

Key Highlights

  • The Upstream Bio transaction was priced at $5.49 per share.
  • Deykin Aaron’s reported ownership after the sale stood at 32,302 shares.
  • The transaction represented about 2.7% of Aaron’s prior Upstream Bio holding.

Deykin Aaron sold 895 shares of Upstream Bio (NASDAQ: UPB) at $5.49 per share on Sept. 16, 2026. The transaction left Aaron with 32,302 shares, while the sale represented about 2.7% of his previous holding in Upstream Bio.

Transaction Details and Sale Classification

Aaron is identified as Upstream Bio’s Chief Medical Officer. The reported activity involved 895 Upstream Bio shares changing hands at the stated per-share price. The transaction date was Sept. 16, 2026. Upstream Bio is the company connected to Aaron’s reported share ownership.